OpenAI acquires Orchestra Bio to build AI agents that speed up drug development
OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spo…
以下正文同步自 The Decoder，版权归原站所有，已转换为易读排版。
OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems. Developing a new drug in the US takes ten to 15 years on average. OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research. The article OpenAI acquires Orchestra Bio to build AI agents that speed up drug development appeared first on The Decoder.
正文由 探How 从来源站点 RSS 同步，内容未经改写；遇到排版缺失或需要图片、视频时请以原文为准。